000K  utf8
1100  2019$c2019-03-28
1500  eng
2050  urn:nbn:de:hbz:464-20220217-143648-5
2051  10.1159/000497101
3000  Pietzsch, Jan Benjamin
3010  Biermann-Stallwitz, Janine
3010  Geisler, Benjamin P.
3010  Liu, Shan
3010  Randerath, Winfried
3010  Richter, Ann-Kathrin
3010  Steffen, Armin
3010  Wasem, Jürgen
4000  Clinical and Economic Benefits of Upper Airway Stimulation for Obstructive Sleep Apnea in a European Setting  [Pietzsch, Jan Benjamin]
4209  Background: Upper airway stimulation (UAS) is a treatment approach for patients with moderate-to-severe obstructive sleep apnea who cannot adhere to continuous positive airway pressure therapy. Objective: The objective was to evaluate added patient benefit and cost-effectiveness of UAS in the German health care system. Methods: We used a decision-analytic Markov model to project major adverse cardiovascular or cerebrovascular events (myocardial infarction [MI] or stroke), motor vehicle collision (MVC), mortality, quality-adjusted life years (QALYs), and costs. The assumed reduction in the apnea-hypopnea index with UAS compared to no treatment is based on German real-world data. Other input data were derived from the literature, public statistics, and multivariate regression. Cost-effectiveness was evaluated in Euros per QALY gained, both discounted at 3%. Results: UAS was projected to reduce event risks (10-year relative risk for stroke, MI, cardiovascular death, and MVC: 0.76, 0.64, 0.65, and 0.34, respectively), and to increase survival by 1.27 years. While the UAS strategy incurred an additional 1.02 QALYs within the patient lifetime, there were also additional costs of EUR 45,196, resulting in an incremental cost-effectiveness ratio of EUR 44,446 per QALY gained. Conclusions: In the present model-based analysis, UAS therapy provides meaningful benefit to patient-relevant endpoints and is a cost-effective therapy in the German setting.
4950  https://doi.org/10.1159/000497101$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:hbz:464-20220217-143648-5$xR$3Volltext$534
4961  https://duepublico2.uni-due.de/receive/duepublico_mods_00072255
5051  610
5550  Cost-benefit analysis
5550  Cost-effectiveness analysis
5550  Decision support techniques
5550  Implantable pulse generator
5550  Markov model
5550  Obstructive sleep apnea
5550  Sleep apnea
5550  Upper airway stimulation